PHI with Ulcerative rectosigmoiditis
How does this condition affect your private health insurance?
Rektosigmoiditis ulceröse is a localized form of ulcerative colitis, a chronic inflammatory bowel disease affecting the rectum and the sigmoid colon. It is characterized by inflammation and ulceration of the innermost lining of these sections of the large intestine. Common symptoms include bloody diarrhea, urgency to defecate, tenesmus, and abdominal cramps. While typically milder than more extensive forms of ulcerative colitis, it can significantly impact quality of life. Treatment focuses on reducing inflammation and maintaining remission, often through topical or oral medications like aminosalicylates, and sometimes corticosteroids or biologics.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Weeks to months without treatment; initial flare can be prolonged.
Duration of Illness (Lifetime)
Chronic, lifelong disease with periods of remission and relapse.
Cost of Treatment (Initial)
Approximately $500 - $5,000 for initial diagnosis and medication, depending on severity and investigations.
Cost of Treatment (Lifetime)
Ranges from $50,000 to $500,000+ over a lifetime, including regular medications, follow-up, and potential advanced therapies for flares.
Mortality Rate
Very low directly from rectosigmoiditis; increased slightly by severe complications like toxic megacolon (rare) or long-term colorectal cancer risk.
Risk of Secondary Damages
High. Includes anemia, nutritional deficiencies, extraintestinal manifestations (e.g., joint pain, skin lesions), increased risk of colorectal cancer over long periods, and psychological impact (anxiety, depression).
Probability of Full Recovery
Very low. Ulcerative colitis is generally incurable, though long-term remission is achievable with treatment. Surgical removal of the colon (proctocolectomy) is curative for the intestinal disease but has its own consequences.
Underlying Disease Risk
Moderate. Patients may develop other autoimmune conditions (e.g., primary sclerosing cholangitis, ankylosing spondylitis) or, with long-standing disease, colorectal cancer. Not an underlying disease that causes it, but comorbidities.